Our aim is to advance the care of critically ill patients
From our technicians to our CEO, here you’ll find individuals whose
actions speak louder than words—people who strive to make a difference
in the lives of critically ill patients and the clinicians who care for
Chief Executive Officer
“When people become critically ill, their entire world changes—they are fully reliant on healthcare professionals, drugs, and technology. They have no choice. That's where we can make a real difference. By providing advanced therapies and support to the professionals who treat them in the most crucial moments of their lives, we can give them the solutions that no one else is offering.”
Daniel Tassé has served as our President, Chief Executive Officer, and a member of our board of directors since January 2008. Mr Tassé was appointed Chairman in October 2009. Prior to joining us, from October 2004 to January 2008, Mr Tassé served as General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc., a global diversified healthcare company. Baxter's Pharmaceuticals and Technologies Business Unit includes the Anesthesia and Critical Care business, the Hospital IV Drug business, the Contract Manufacturing business, and the Formulation Technology business. From July 2001 to October 2004, Mr Tassé served as Vice President and Regional Director for Australasia at GlaxoSmithKline, a healthcare company. Mr Tassé holds a BS in Biochemistry from the University of Montreal. As our President and Chief Executive Officer, Mr Tassé provides a critical contribution to our board of directors as a result of his extensive track record of business building in the healthcare industry, his strong background within critical care, his global management experience, and his detailed knowledge of the pharmaceutical industry, our company, employees, client base, and competitors.
MATTHEW M. BENNETT
Executive Vice President
Global Medical Operations and
“How many people can say they actually look forward to going to work in the morning? I feel fortunate to be part of this group. Working with a team of highly passionate people who strive to advance science beyond where it has ever been before is something that I am excited to be a part of.”
Matthew M. Bennett currently serves as our Executive Vice President, Global Medical Operations and General Counsel. Mr. Bennett first began his tenure as our Senior Vice President, Legal and Corporate Development in July 2007. Prior to joining us, from October 2003 to July 2007, Mr Bennett held several positions of increasing responsibility, including Executive Vice President, General Counsel and Chief Administrative Officer at Viasys Healthcare, Inc., a healthcare technology company, where he was responsible for legal matters, business development, quality, regulatory affairs, and human resources. From August 1997 to October 2003, Mr Bennett was an attorney at Morgan, Lewis & Bockius LLP and was previously a litigator at Stradley, Ronon, Stevens & Young LLP. Mr Bennett holds an AB in Political Science from Princeton University and a JD from Villanova University School of Law.
Executive Vice President
Chief Administration Officer and
“When people ask me what we do at Ikaria, my answer is simple: People who work at Ikaria are here to do more than just a job. Our employees are a special group...from our scientists to our distribution associates.”
James Briggs currently serves as our Executive Vice President, Chief Administration Officer and Operations. Mr. Briggs first began his tenure as our Senior Vice President, Human Resources in August 2008. Prior to joining us, from March 2007 to August 2008, Mr Briggs served as Director, Human Resources at Avaya Global Services, a global IP telephone products and services company. From April 2004 to March 2007, Mr Briggs served as Vice President, Human Resources at General Electric's Access Distribution Unit, a global IT distributor. Prior to joining General Electric, he held several positions at Unilever, an international manufacturer of food, home care, and personal care products, and The Pepsi Bottling Company, a manufacturer and distributor of Pepsi-Cola products. Mr Briggs holds a BA in Communications and an MA in Human Resources and Industrial Relations from the University of Illinois.
DOUGLAS GREENE, MD
Executive Vice President and
Chief Scientific Officer
“Only by listening to clinicians, understanding their needs, and observing their challenges firsthand can we fully respond to the complexities of critical care. Our development of therapies is constantly refined by our presence in, commitment to, and passion for this complex arena. Together, we will advance critical care to the next level.”
Douglas Greene, MD, has served as our Executive Vice President, Research and Development since June 2010. Prior to joining us, from April 2009 to April 2010, Dr Greene served as Senior Vice President and Senior Scientific Advisor at Sanofi-aventis, a global pharmaceutical company. From August 2006 to March 2009, Dr Greene served as Senior Vice President and Chief Medical Officer of the US business at Sanofi-aventis. From June 2003 to July 2006, Dr Greene served as Vice President and Head of Corporate Regulatory Development at Sanofi-aventis. Dr Greene was Executive Vice President of Clinical Sciences and Product Development at Merck Research Laboratories and Corporate Officer of Merck, Inc., a global pharmaceutical company, from May 2000 to January 2003. Dr Greene also was a member of the US Food and Drug Administration's Endocrinologic and Metabolic Drug Advisory Committee from 1988 to 1994, and acted as Chairman of the Advisory Committee from 1990 to 1994. Dr Greene holds an MD from the Johns Hopkins School of Medicine.
TASOS G. KONIDARIS
Executive Vice President
Chief Financial Officer and
“What makes Ikaria different from other companies is that we put words into action. Our goal is to advance critical care, so we invest about a quarter of our revenues in R&D. We also invest in education to improve care, and to fund research, all in the hopes that the quality of clinical research in the future will be in good hands.”
Tasos Konidaris currently serves as our Executive Vice President, Chief Financial Officer and Corporate Development. Mr. Konidaris first began his tenure as our Senior Vice President and Chief Financial Officer in October 2011. Prior to joining us, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D&B) Corporation, a leading commercial information services company. He was Principal Accounting Officer and led the Global Finance Operations of D&B beginning in 2005. From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company. Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris holds an MBA from Drexel University, and a BS from Gwynedd Mercy College.
Executive Vice President
Chief Commercial Officer
“Having a clear, well-articulated corporate vision is important, but the true value of a company lies in its ability to make a difference in the lives of patients. To stand side-by-side with a respiratory therapist in a NICU and see a baby who was previously struggling to get enough oxygen turn a healthy pink color—that makes me so very proud of what we do.”
Stephen Ross currently serves as our Executive Vice President, Chief Commercial Officer. Mr. Ross first began his tenure as our Senior Vice President, Commercial Operations in August 2008. Prior to joining us, from July 2007 to August 2008, Mr Ross served as Senior Vice President, Sales and Marketing at Cytogen Corporation, a specialty pharmaceutical company. From October 2002 to June 2007, he held several positions, including Vice President, Specialty Business Units, at GlaxoSmithKline, a healthcare company. Mr Ross holds a BA in Economics from Brigham Young University and an MBA from The Wharton School of the University of Pennsylvania.